Health care stocks were lower Monday afternoon, with the NYSE Health Care Index easing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%.
The iShares Biotechnology ETF (IBB) shed 0.2%.
In corporate news, AbbVie (ABBV) shares tumbled 12%. The company said its two phase 2 trials assessing emraclidine in adult patients with schizophrenia and acute exacerbation of psychotic symptoms failed to meet their primary goal.
Cigna (CI) shares climbed past 7%. The health insurer said it's not pursuing a combination with Humana (HUM) and is on track to meet its full-year earnings target. Humana shares fell almost 2%.
Novavax (NVAX) said Monday that the US Food and Drug Administration has lifted a clinical hold on an investigational new-drug application for its Covid-Influenza combination and stand-alone flu vaccine candidates. Its shares popped 2%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。